-
71.发明公开
公开(公告)号：KR1020140036371A
公开(公告)日：2014-03-26
申请号：KR1020120100851
申请日：2012-09-12
Applicant: 한국식품연구원 , 호서대학교 산학협력단
IPC: A61K31/075 , A61K31/085 , A61P3/10 , A61P3/00
Abstract: The present invention provides a composition for preventing, relieving, curing, and treating insulin resistance and type 2 diabetes comprising capsiate as an active ingredient. The composition of the present invention improves insulin secretion and insulin sensitivity, reduces insulin resistance, and improves the proliferation of pancreatic β-cell for offering an excellent effect on preventing and treating insulin resistance and type 2 diabetes. The present invention provides a pharmaceutical composition for preventing, relieving, curing, and treating insulin resistance and type 2 diabetes comprising capsiate as an active ingredient. The present invention provides a food composition for preventing, relieving, and treating insulin resistance and type 2 diabetes comprising capsiate as an active ingredient.
Abstract translation: 本发明提供了一种用于预防，缓解，治愈和治疗胰岛素抵抗的组合物和包括作为活性成分的2型糖尿病。 本发明的组合物改善了胰岛素分泌和胰岛素敏感性，降低了胰岛素抵抗，改善了胰腺β细胞的增殖，为预防和治疗胰岛素抵抗和2型糖尿病提供了极好的效果。 本发明提供一种用于预防，缓解，治愈和治疗胰岛素抵抗的药物组合物和包括作为活性成分的2型糖尿病。 本发明提供了一种用于预防，缓解和治疗胰岛素抵抗的食物组合物和包含作为活性成分的2型糖尿病。
-
公开(公告)号：KR1020130087904A
公开(公告)日：2013-08-07
申请号：KR1020120009153
申请日：2012-01-30
Applicant: 한국식품연구원
CPC classification number: A61K36/28 , A23L11/09 , A23L33/105 , A23V2200/328 , A61K36/48 , Y10S514/893
Abstract: PURPOSE: A composition containing Jerusalem Artichoke and cheonggukjang as active ingredients for preventing or treating metabolic diseases is provided to reduce fasting blood sugar and insulin resistance, to suppress the increase of blood glucose, and to increase insulin secretion, thereby effectively preventing and treating diabetes. CONSTITUTION: A composition for preventing or treating metabolic diseases contains Jerusalem Artichoke and cheonggukjang as active ingredients. The metabolic diseases are diabetes or fatty liver. Jerusalem Artichoke and cheonggukjang are a powder type. Cheonggukjang contains 0.08 ug/g to 0.01 mg/g of diadzein. The composition reduces fasting blood sugar.
Abstract translation: 目的：提供一种含有耶路撒冷朝鲜蓟和cheonggukjang作为预防或治疗代谢性疾病的有效成分的组合物，以减少空腹血糖和胰岛素抵抗，抑制血糖升高，增加胰岛素分泌，从而有效预防和治疗糖尿病。 构成：用于预防或治疗代谢疾病的组合物含有耶路撒冷朝鲜蓟和cheonggukjang作为活性成分。 代谢疾病是糖尿病或脂肪肝。 耶路撒冷朝鲜蓟和长江口是粉末型。 清胃ang含有0.08μg/ g至0.01mg / g的二氢。嗪。 该组合物减少空腹血糖。
-
公开(公告)号：KR1020130078326A
公开(公告)日：2013-07-10
申请号：KR1020110147201
申请日：2011-12-30
Applicant: 한국식품연구원
IPC: A61K31/353 , A61K9/08 , A61P17/00
Abstract: PURPOSE: A pharmaceutical composition containing auraptene as an active ingredient for promoting angiogenesis is provided to promote angiogenesis by auraptene, and to effectively regenerate tissues through skin flap regeneration, wound and burn healing, and artificial skin transplantation. CONSTITUTION: A pharmaceutical composition for promoting angiogenesis contains 1-10 micromole of auraptene as an active ingredient. Auraptene promotes tissue regeneration. The pharmaceutical composition is used for skin flap regeneration, wound and burn healing, artificial skin transplantation, or preparation of blood vessels for transplantation. A food composition for promoting angiogenesis contains auraptene as an active ingredient. Auraptene promotes angiogenesis. [Reference numerals] (AA) Control group; (BB) Auraptene 1μM; (CC) Auraptene 5μM; (DD) Auraptene 10μM; (EE) Auraptene 40μM
Abstract translation: 目的：提供含有紫罗烯作为促进血管发生的活性成分的药物组合物，用于促进紫罗烯烯的血管生成，并通过皮瓣再生，伤口和烧伤愈合以及人造皮肤移植有效地再生组织。 构成：用于促进血管发生的药物组合物含有1-10微摩尔的奥来哌啶作为活性成分。 Auraptene促进组织再生。 药物组合物用于皮瓣再生，伤口和烧伤愈合，人造皮肤移植或用于移植的血管制备。 用于促进血管生成的食品组合物含有作为活性成分的紫罗烯。 Auraptene促进血管生成。 （附图标记）（AA）对照组; （BB）Auraptene1μM; （CC）Auraptene5μM; （DD）Auraptene10μM; （EE）Auraptene40μM
-
公开(公告)号：KR101259130B1
公开(公告)日：2013-04-30
申请号：KR1020110027799
申请日：2011-03-28
Applicant: 한국식품연구원
Abstract: 본 발명은 모바일 기반의 개인 맞춤형 추천식품 제공시스템 및 그 제공방법에 관한 것으로, 개인의 건강상태 및 모발분석을 통해 개인마다 가장 적합한 식품을 모바일을 기반으로 추천하고 이 추천된 식품을 이용하여 개인 맞춤형 식단을 제공함으로써 장소 및 시간의 제약을 받지 않고 언제 어디서나 손쉽고 편리하게 서비스를 이용할 수 있도록 한 것이다.
-
公开(公告)号：KR1020130021422A
公开(公告)日：2013-03-05
申请号：KR1020130001241
申请日：2013-01-04
Applicant: 주식회사디엔에이링크 , 한국식품연구원
CPC classification number: C12Q1/6883 , C12N15/11 , C12Q1/6837 , C12Q2600/156
Abstract: PURPOSE: A polynucleotide for diagnosing a risk of developing metabolic syndrome is provided to quickly and effectively diagnose a risk of developing metabolic syndrome of an individual. CONSTITUTION: A polynucleotide for diagnosing a risk of developing metabolic syndrome of an individual with obesity is selected from the group consisting of sequence numbers 2-4, or a complementary polynucleotide thereof. The polynucleotide has 10 or more continuous nucleotides with SNP at 101th base of sequence numbers 2-4.
Abstract translation: 目的：提供用于诊断发生代谢综合征风险的多核苷酸，以快速有效地诊断发生个体代谢综合征的风险。 构成：用于诊断患有肥胖个体的代谢综合征风险的多核苷酸选自序列号2-4或其互补多核苷酸。 该多核苷酸在序列号2-4的第101位具有10个或更多个具有SNP的连续核苷酸。
-
Patent Agency Ranking
公开(公告)号：KR1020120134090A
公开(公告)日：2012-12-11
申请号：KR1020120120480
申请日：2012-10-29
Applicant: 한국식품연구원
Abstract: PURPOSE: A peptide which suppresses HMG-CoA reductase is provided to competitively suppress the enzyme and to obtain a cholesterol synthesis inhibitor which treats cardiovascular diseases. CONSTITUTION: A peptide contains one or more sequences selected from the group consisting of sequence numbers 1-5. The peptide competitively suppresses HMG-CoA redutase. A cholesterol synthesis inhibitor contains the peptide containing a sequence selected from the group consisting of sequence numbers 1-5. The cholesterol synthesis inhibitor is used for preventing and treating cardiovascular diseases.
Abstract translation: 目的：提供抑制HMG-CoA还原酶的肽，以竞争性地抑制酶并获得治疗心血管疾病的胆固醇合成抑制剂。 构成：肽含有选自序列号1-5的一个或多个序列。 该肽竞争性地抑制HMG-CoA反义。 胆固醇合成抑制剂含有含有选自序列号1-5的序列的肽。 胆固醇合成抑制剂用于预防和治疗心血管疾病。
-
公开(公告)号：KR1020120054416A
公开(公告)日：2012-05-30
申请号：KR1020100115775
申请日：2010-11-19
Applicant: 한국식품연구원
Abstract: PURPOSE: A peptide which suppresses HMG-CoA reductase is provided to suppress cholesterol synthesis and to treat cardiovascular diseases. CONSTITUTION: A peptide which suppresses HMG-CoA reductase contains a sequence selected from sequence numbers 1-5. A cholesterol synthesis inhibitor contains the peptide. The cholesterol synthesis inhibitor is used for treating cardiovascular diseases.
Abstract translation: 目的：提供抑制HMG-CoA还原酶的肽，以抑制胆固醇合成和治疗心血管疾病。 构成：抑制HMG-CoA还原酶的肽含有选自序列号1-5的序列。 胆固醇合成抑制剂含有肽。 胆固醇合成抑制剂用于治疗心血管疾病。
-
公开(公告)号：KR1020120048205A
公开(公告)日：2012-05-15
申请号：KR1020100109716
申请日：2010-11-05
Applicant: 한국식품연구원
IPC: A61K31/198 , A61P3/04 , A61P3/06 , A61P3/10
Abstract: PURPOSE: A pharmaceutical composition and health food containing methylselenocystein is provided to prevent and treat obesity and lipid-related metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-related metabolic diseases contains methylselenocysteine as an active ingredient. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, oral formulation of aerosol, external use, suppository, or sterilized injection solution. A health food for preventing and relieving obesity and metabolic diseases contains methylselenocystein as an active ingredient. The health food is manufactured in the form of capsules, tablets, granules, powder, or beverage.
Abstract translation: 目的：提供含有甲基硒代半胱氨酸的药物组合物和保健食品，用于预防和治疗肥胖症和与脂质有关的代谢疾病。 构成：用于预防和治疗肥胖症和脂质相关代谢疾病的药物组合物含有甲基硒代半胱氨酸作为活性成分。 该组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，气雾剂口服制剂，外用，栓剂或灭菌注射液的形式制备。 用于预防和缓解肥胖和代谢疾病的保健食品含有甲基硒代半胱氨酸作为活性成分。 保健食品以胶囊，片剂，颗粒，粉末或饮料的形式制造。
-
公开(公告)号：KR1020120004828A
公开(公告)日：2012-01-13
申请号：KR1020100065515
申请日：2010-07-07
Applicant: 한국식품연구원
IPC: A61K31/05 , A61K31/045 , A61P29/00
Abstract: PURPOSE: A 2,4 D-tertiary-butylphenol or salt thereof for anti-inflammation is provided to suppress iNOS expression and to prevent and treat inflammation. CONSTITUTION: An anti-inflammatory composition contains 2,4 D-tertiary-butylphenol or salt thereof as an active ingredient. A pharmaceutical composition for preventing and treating inflammation contains 2,4 D-tertiary phenol or pharmacologically acceptable salt thereof as an active ingredient. A food composition for preventing and treating inflammation contains 0.01-10 wt% of 2,4-D-tertiary-butylphenol or sitologically acceptable salt thereof as an active ingredient. The salt is acid addition salt.
Abstract translation: 目的：提供用于抗炎的2,4-二叔丁基苯酚或其盐以抑制iNOS表达并预防和治疗炎症。 构成：抗炎组合物含有2,4-二叔丁基苯酚或其盐作为活性成分。 用于预防和治疗炎症的药物组合物含有2,4-二叔酚或其药理学上可接受的盐作为活性成分。 用于预防和治疗炎症的食品组合物含有0.01-10重量％的2,4-D-叔丁基苯酚或其可以选择的盐作为活性成分。 盐是酸加成盐。
-
公开(公告)号：KR1020110049281A
公开(公告)日：2011-05-12
申请号：KR1020090106227
申请日：2009-11-04
Applicant: 한국식품연구원
IPC: A61K31/355 , A61P3/04 , A23L1/30
Abstract: PURPOSE: An anti-obesity composition containing lycopene or pharmacologically acceptable salt thereof is provided to ensure excellent anti-obesity activity without side effect. CONSTITUTION: An anti-obesity composition contains 0.001-10 weight% of lycopene or pharmacologically acceptable salt thereof as an active ingredient. The anti-obesity composition further contains 0.001-10 weight% of gingerol or pharmacologically acceptable salt thereof as an active ingredient.
Abstract translation: 目的：提供含有番茄红素或其药理学上可接受的盐的抗肥胖组合物以确保优异的抗肥胖活性而没有副作用。 构成：抗肥胖组合物含有0.001-10重量％的番茄红素或其药理学上可接受的盐作为活性成分。 抗肥胖组合物还含有0.001-10重量％的姜油或其药理学上可接受的盐作为活性成分。
-
-
-
-
-
-
-
-
-
Search Results
109
records
(took 0.029 seconds)
